Trodelvy 180 mg injection

The drug Sacituzumab govitecan-hziy is used to treat patients with unresectable locally advanced or metastatic triple-negative breast carcinoma and locally advanced or metastatic urothelial carcinoma by healthcare professionals. The active ingredient in the medicine, Sacituzumab govitecan-hziy, is a Trop-2-directed antibody and topoisomerase inhibitor conjugate. The recombinant monoclonal antibody (Sacituzumab govitecan-hziy) is produced by mammalian cells, while the small molecule components SN-38 and CL2A are produced via chemical synthesis. This medicine is supplied in 180 mg in single-use vials for intravenous infusion.
Trodelvy 180 mg injection is readily available from several generic medicine suppliers. To know more about this drug, dial 1800-889-1064.
Tweet